Including skin reaction-related treatment-emergent adverse events , the proportion of women who experienced any treatment-emergent adverse event was similar among women randomized to the contraceptive patch ( 47.5 % ) , the combination oral contraceptive 20 ( 47.4 % ) , or the combination oral contraceptive 30 ( 46.8 % ) .